MedTech research and development company Medinol Inc announced on Thursday that its subsidiary Microtech has started human clinical trials of its microsensor platform, in a trial to assess atrial pressures important for the treatment of heart failure.
The first implantation was recently conducted by Prof. Erez Sharoni at Beilinson Medical Centre in Petah-Tikva, Israel.
The Microtech implantable microsensor platform is the result of decades of development in a new class of sensor technology that can be used both as a stand-alone device or integrated with existing devices.
Prof. Sharoni, head of Cardio-Thoracic Surgery, said: "This amazing technology may change the standard of care for patients suffering from heart failure and in particular, in this current study, those who are receiving LVADs or heart transplants."
Duality Biologics reveals B7H4 ADC milestone achievement and license exercise by BeiGene
Precigen submits BLA for PRGN-2012 for treatment of recurrent respiratory papillomatosis
Novartis Phase III study of intrathecal onasemnogene abeparvovec meets primary endpoint in SMA
Hemogenyx Pharmaceuticals announces first clinical site for HG-CT-1 Phase I trial
Ondine Biomedical enrolls first patient in US Phase 3 trial
IDEAYA Biosciences enters license agreement with Jiangsu Hengrui Pharmaceuticals
Huadong Medicine collaborates with SynerK
Microtech commences human clinical trial of microsensor platform for heart failure